xmab18087
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 22, 2018 (NCT03411915)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Somatostatin receptor 2INHIBITOR
SSTR2 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04590781 | Phase 1/Phase 2 (Phase 2) | May 10, 2021 | ICON, Xencor |
| NCT03411915 | Phase 1 | Jan 22, 2018 | ICON, Xencor |
Showing 2 of 2 trials
Page 1 / 1